Today the Supreme Court granted review in Federal Trade Comm'n v. Watson Pharmaceuticals, No. 12-416 (U.S.), an antitrust case that presents the question of whether section 1 of the Sherman Act bars Competitor A from paying Competitor B to delay rolling out a generic drug that vies for sales with Competitor A's brand-name drug. Posts here and here.